Advertisement
BIO vs TMO
Which Stock Would AI Choose? Bio-Rad Laboratories (BIO) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- BIO and TMO operate in the life sciences and diagnostics sector, with TMO maintaining a significantly larger market capitalization and broader segment exposure.
- Recent market activity shows TMO delivering 5% organic revenue growth in its second quarter and raising full-year guidance, while BIO reported a quarterly earnings beat amid mixed end-market conditions.
- Both companies have faced varying pressures in academic and international markets, yet TMO has highlighted improving demand from pharmaceutical and biotechnology customers.
- Stock performance over recent months reflects stronger momentum for TMO following its results, contrasted with more variable reactions for BIO.
- Sector exposure differs notably, with TMO benefiting from diversified analytical instruments and biopharma services alongside diagnostics.
- Market sentiment appears supported by conference participation and analyst commentary for both, though scale and execution consistency favor larger peers in the current environment.
Introduction
Bio-Rad Laboratories (BIO) and Thermo Fisher Scientific (TMO) represent key players in the life science research, clinical diagnostics, and analytical instruments space. This comparison examines their relative positioning, recent performance trends, and business drivers within the healthcare sector. Institutional investors, sector-focused traders, and those monitoring biotechnology tools and diagnostics may find the analysis relevant for assessing market positioning and volatility patterns. The review draws on observable financial metrics and developments to highlight contrasts in scale, growth exposure, and operational resilience.
BIO Overview and Recent Performance
Bio-Rad Laboratories develops and distributes life science research and clinical diagnostic products, operating primarily through Life Science and Clinical Diagnostics segments. The company serves research institutions, biopharmaceutical manufacturers, and clinical laboratories worldwide. In recent market activity, shares have shown gains over the trailing three months amid quarterly results that exceeded expectations on both revenue and adjusted earnings. Management noted improving trends in digital PCR and diagnostics, though academic and certain international markets remained cautious. Conference appearances and analyst price target adjustments have contributed to sentiment in recent weeks, with the stock trading within a defined 52-week range reflecting broader sector dynamics.
TMO Overview and Recent Performance
Thermo Fisher Scientific provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products through four main segments. The company supports pharmaceutical, biotechnology, academic, and industrial customers globally. Recent market activity featured second-quarter organic revenue growth of 5% and an adjusted earnings beat, prompting an upward revision to full-year 2026 guidance. Strength in pharma and biotech end markets, alongside portfolio optimization steps such as divestitures, supported the outlook. Shares responded positively to the results, with the company maintaining a medium-term organic growth expectation in the 3% to 6% range amid ongoing operational execution.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots designed for various market conditions. Tickeron offers hundreds of AI Trading Bots that trade thousands of different tickers, yet only those demonstrating strong suitability for prevailing environments earn placement in the trending section. Available bots encompass a wide range of trading styles, strategies, timeframes, performances, and statistics, with performance metrics varying across equity, options, and other instruments. Traders seeking data-driven approaches may review the page for details on bot parameters and historical outcomes.
Head-to-Head Comparison
BIO operates as a more specialized provider with concentrated exposure to research tools and diagnostics, resulting in a smaller market capitalization and potentially higher sensitivity to funding cycles in academia and biopharma. In contrast, TMO benefits from greater scale, diversified revenue streams across analytical instruments and biopharma services, and broader customer reach that has translated into steadier recent organic growth. Momentum in recent quarters favors TMO following its guidance raise, while BIO has navigated mixed end-market conditions with targeted product strength in areas such as digital PCR. Risk factors include execution on international markets for both, though TMO’s larger footprint may offer relative stability. Sector sentiment remains tied to biotechnology spending trends, with TMO positioned for wider participation in recovery signals.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings delivery, and positive guidance adjustments, Tickeron’s AI would currently assign a higher probabilistic weighting to TMO in comparative positioning. The company’s demonstrated organic growth acceleration and raised outlook provide clearer near-term catalysts relative to the more variable performance backdrop for BIO. This assessment reflects data-driven evaluation rather than forecasts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIO is a Hold and TMO is a Hold.
BIO in downward trend: 10-day moving average moved below 50-day moving average on October 12, 2026
The 10-day moving average for BIO crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BIO as a result. In 70 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
BIO moved below its 50-day moving average on October 07, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
The Aroon Indicator for BIO entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BIO's RSI Oscillator exited the oversold zone, 18 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 64%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 60 cases where BIO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
Following a +6.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIO advanced for three days, in 199 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
BIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. BIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 87 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.408) is normal, around the industry mean (10.930). P/E Ratio (46.004) is within average values for comparable stocks, (100.178). Projected Growth (PEG Ratio) (4.006) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (3.940) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
TMO sees its Stochastic Oscillator climbs out of oversold territory
On October 09, 2026, the Stochastic Oscillator for TMO moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 55 instances where the indicator left the oversold zone. In 35 of the 55 cases the stock moved higher in the following days. This puts the odds of a move higher at over 64%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +0.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where TMO advanced for three days, in 196 of 312 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 149 of 250 cases where TMO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 60%.
Bearish Trend Analysis
The 10-day RSI Indicator for TMO moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 23 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 61%.
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TMO as a result. In 48 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 55%.
The Moving Average Convergence Divergence Histogram (MACD) for TMO turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 26 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.
TMO broke above its upper Bollinger Band on September 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.762) is normal, around the industry mean (72.578). P/E Ratio (36.523) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (2.021) is also within normal values, averaging (3.473). Dividend Yield (0.003) settles around the average of (0.001) among similar stocks. P/S Ratio (5.247) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 17 (best 1 - 100 worst), indicating outstanding price growth. TMO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 60 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 73 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TMO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock better than average.
BIO | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 79 | 39 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 88 Overvalued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 73 | |
SMR RATING 1..100 | 87 | 60 | |
PRICE GROWTH RATING 1..100 | 41 | 17 | |
P/E GROWTH RATING 1..100 | 8 | 15 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (13) in the Medical Specialties industry is significantly better than the same rating for BIO (88). This means that TMO’s stock grew significantly faster than BIO’s over the last 12 months.
TMO's Profit vs Risk Rating (73) in the Medical Specialties industry is in the same range as BIO (100). This means that TMO’s stock grew similarly to BIO’s over the last 12 months.
TMO's SMR Rating (60) in the Medical Specialties industry is in the same range as BIO (87). This means that TMO’s stock grew similarly to BIO’s over the last 12 months.
TMO's Price Growth Rating (17) in the Medical Specialties industry is in the same range as BIO (41). This means that TMO’s stock grew similarly to BIO’s over the last 12 months.
BIO's P/E Growth Rating (8) in the Medical Specialties industry is in the same range as TMO (15). This means that BIO’s stock grew similarly to TMO’s over the last 12 months.
| BIO | TMO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 64% | 2 days ago 61% |
| Stochastic ODDS (%) | 2 days ago 77% | 2 days ago 64% |
| Momentum ODDS (%) | 2 days ago 73% | 2 days ago 55% |
| MACD ODDS (%) | N/A | 2 days ago 62% |
| TrendWeek ODDS (%) | 2 days ago 67% | 2 days ago 62% |
| TrendMonth ODDS (%) | 2 days ago 73% | 2 days ago 62% |
| Advances ODDS (%) | 10 days ago 66% | 2 days ago 63% |
| Declines ODDS (%) | 2 days ago 69% | 14 days ago 62% |
| BollingerBands ODDS (%) | 2 days ago 65% | 2 days ago 61% |
| Aroon ODDS (%) | 2 days ago 81% | 2 days ago 60% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIO’s FA Score shows that 1 FA rating(s) are green while TMO’s FA Score has 3 green FA rating(s).
- BIO’s FA Score: 1 green, 4 red.
- TMO’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIO’s TA Score shows that 4 TA indicator(s) are bullish while TMO’s TA Score has 3 bullish TA indicator(s).
- BIO’s TA Score: 4 bullish, 5 bearish.
- TMO’s TA Score: 3 bullish, 5 bearish.
Price Growth
BIO (@Medical/Nursing Services) experienced а -1.38% price change this week, while TMO (@Medical Specialties) price change was +0.98% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -4.83%. For the same industry, the average monthly price growth was -7.52%, and the average quarterly price growth was -14.90%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.34%. For the same industry, the average monthly price growth was -0.09%, and the average quarterly price growth was +34.80%.
Reported Earning Dates
BIO is expected to report earnings on Oct 22, 2026.
TMO is expected to report earnings on Oct 21, 2026.
Industries' Descriptions
@Medical/Nursing Services (-4.83% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-3.34% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IDRV | 32.78 | 0.14 | +0.43% |
| iShares Self-driving EV & Tech ETF (IDRV) | |||
| BBN | 14.42 | 0.02 | +0.14% |
| BlackRock Taxable Municipal | |||
| SMOM | 29.77 | 0.02 | +0.08% |
| Symmetry Panoramic Sector Momentum ETF (SMOM) | |||
| VB | 288.16 | N/A | N/A |
| Vanguard Morningstar Small-Cap ETF (VB) | |||
| RULE | 30.94 | -0.11 | -0.34% |
| Adaptive Core ETF (RULE) | |||
TMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.
| Ticker / NAME | Correlation To TMO | 1D Price Change % | ||
|---|---|---|---|---|
| TMO | 100% | +0.12% | ||
| A - TMO | 74% Closely correlated | +0.16% | ||
| DHR - TMO | 71% Closely correlated | +0.74% | ||
| RVTY - TMO | 70% Closely correlated | -0.34% | ||
| IQV - TMO | 68% Closely correlated | -0.58% | ||
| BRKR - TMO | 67% Closely correlated | -0.11% | ||
More | ||||